Prognostic Factors Affecting TACE Combined With RFA In Treatment Of Patients With BCLC Stage B And C

Objective:To explore the factors influencing the median progression-free survival(PFS)and median survival(OS)of patients with BCLC stage B and C treated by TACE combined with RFA.Methods: A total of 66 patients with BCLC stage B and C were included in the study.Retrospectively collecting follow-up data,using SPSS19.0statistical software to calculate the median PFS and median OS of patients.Using Kaplan-Meier single factor analysis to analyze the single factors of the variables that may affect the median PFS and median OS,and then COX multi-factor analysis is carried out to determine the main influencing factors.Results: The median disease-free progressive survival(Media PFS)of 66 patients with advanced BCLC treated with TACE and RFA was(15+2.708)months,95%CI(9.692,20.308),median survival(Media OS)was(26+1.625)months and 95%CI(22.815,29.185).Kaplan-Meier univariate analysis showed that the variables associated with Media PFS included Child-Pugh classification of liver function,tumor size,number of tumors,portal vein thrombus,frequency of RFA treatment and tegiol treatment.Kaplan-Meier univariate analysis showed that the variables related to Media OS included physical condition(PS score),Child-Pugh grading of liver function,alpha-fetoprotein(AFP)level,tumor size,number of tumors,portal vein cancer thrombus,frequency of RFA treatment and tegio treatment.Cox multivariate regression analysis showed that the positive factors affecting Media PFS were the times of Tegio treatment and RFA treatment,and the inhibitory factors affecting Media PFS and Media OS were portal vein cancer thrombus.Conclusion: Increasing the frequency of RFA treatment or adjuvant tegio therapy is helpful to control the progression of patients with BCLC stage B and C.Portal vein cancer thrombus as an independent factor affects the survival time ofpatients with BCLC stage B and C.